GLB1 and GM1 gangliosidosis: Recently, an adeno-associated virus serotype 9 (AAV9) gene therapy has been developed for GM1 gangliosidosis [109] and clinical trials for this treatment began in 2019 (GM1 Gangliosidosis Gene Therapy Trial (AAV9-GLB1), Clinical trial No. NCT03952637.